Dr. Yaron Turpaz is a proven research and development Informatics, data sciences and technology leader in the biotech and pharma space with hands on experience using cloud based high throughput computational and genomics platforms for drug discovery and development applications in precision medicine.
As Chief Data & Technology Officer at Global Gene Corp., and Managing Director of GGC Singapore, Dr. Turpaz is responsible for the enhancement and development of the company's global data and technology infrastructure, advance analytics, data sciences and machine learning, as well as the expansion of GGC’s Asia operations at Singapore.
Dr. Turpaz was previously the Chief Information Officer at Human Longevity, Inc. (HLI), where he was responsible for building and growing the company’s awards winning AWS based genomic and phenotypic KnowledgebaseTM business, and led all bioinformatics/informatics and software engineering efforts, including the launch of the Health Nucleus App and the Medical Avatar that integrates client’s health data with genomics, imaging, metabolome and microbiome metagenome analysis. He expanded the global informatics program at HLI and established teams at San Diego, CA and Singapore, with a focus on collaborations and business development with the pharmaceutical, healthcare and insurance industries. Driving the expansion to Asia, Dr. Turpaz also functioned as the Managing Director of Human Longevity Singapore. Prior to joining HLI, he worked at AstraZeneca as Vice President, R&D IT. In this position he led a global team of approximately 300 and was accountable for the more than $120 million R&D IT budget, leading the development of Big Data analytics, knowledge engineering, real world evidence and scientific informatics solutions across the company’s drug discovery & development pipeline for a variety of therapeutic areas including oncology, diabetes, cardiovascular, neuroscience and infectious diseases. Before AZ, Dr. Turpaz joined the establishment of Eli Lilly Singapore Centre for Drug Discovery as Director of Integrative Computational Sciences, towards in-silico acceleration of drug discovery and biomarker identification for oncology and metabolic diseases. While there, he co-established the Asian Cancer Research Group (ACRG) in collaboration with Merck and Pfizer. The ACRG is a not-for-profit organization conducting genomic and proteomic analysis on cancers prevalent in Asian populations. Prior to joining Lilly, Dr. Turpaz was a Senior Manager, Bioinformatics and Algorithms Development at Affymetrix, Inc. There he managed a team of bioinformaticians, statisticians and software engineers who developed informatics solutions for a variety of GeneChipTM microarray applications. He and his team were contributing to the development and launch of six successful commercial microarray products there.
Dr. Turpaz has a BS in Biology from Tel Aviv University, a Ph.D. in Bioengineering from the University of Illinois and an MBA from the University of Chicago, Booth School of Business. He also held an adjunct assistant professor at the Centre for Quantitative Medicine of Duke-National University of Singapore, Graduate Medical School.